Press "Enter" to skip to content

Novartis wins Medicaid approval for new sickle cell drug in key U.S. states

The approvals from the Florida and Alabama Medicaid health programs for the poor and disabled mark exceptionally fast acceptance for the treatment, which can cost up to $113,000 annually for an individual patient, excluding discounts, said Ameet Mallik, who heads the Swiss drugmaker’s oncology division.

Original source: